Valuation : Compass Therapeutics, Inc.

Market Cap 430M 371M 348M 318M 597M 40.95B 601M 4.12B 1.6B 20.77B 1.62B 1.58B 68.76B P/E 2026 *
-4.77x
P/E 2027 * -4.32x
Enterprise Value 280M 241M 227M 207M 389M 26.68B 392M 2.69B 1.05B 13.53B 1.05B 1.03B 44.8B EV / Sales 2026 *
-
EV / Sales 2027 * 13.3x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day-2.72%
1 week-7.71%
Current month-2.30%
1 month+23.87%
3 months+5.18%
6 months-58.89%
Current year-56.52%
1 week 2.31
Extreme 2.31
2.53
1 month 1.85
Extreme 1.85
2.55
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/29/26 Buy

Controller/Auditor

15,000 0.0083%
4/29/26 Buy

General Counsel

25,000 0.0139%
4/29/26 Free

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
-2.30%-7.71%-31.92%-1.89% 430M
-1.66%-4.96%+49.84%+88.43% 68.13B
+1.60%+1.16%+46.81%+85.99% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
-0.63%-2.20%-16.61%+435.20% 26.6B
-0.38%-10.93%+0.95%-16.57% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
+1.01%+1.66%+30.87%-18.67% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+1.61%-2.60%+48.58%+142.93% 13.54B
Average -1.15%-2.48%+41.27%+164.54% 27.65B
Weighted average by Cap. -0.62%-2.34%+45.79%+143.23%

Financials

2026 *2027 *
Net sales - 22.39M 19.28M 18.1M 16.53M 31.05M 2.13B 31.27M 215M 83.47M 1.08B 84.08M 82.25M 3.58B
Net income -94.04M -80.97M -76.03M -69.4M -130M -8.95B -131M -901M -351M -4.54B -353M -345M -15.02B -110M -94.56M -88.79M -81.05M -152M -10.45B -153M -1.05B -409M -5.3B -412M -403M -17.55B
Net Debt -150M -129M -121M -111M -208M -14.27B -209M -1.44B -559M -7.24B -563M -551M -23.96B -133M -115M -108M -98.15M -184M -12.65B -186M -1.27B -496M -6.42B -499M -489M -21.25B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
26-09-01 US$2.325 -2.72% 209,304
26-08-31 US$2.390 -0.42% 3,523,042
26-08-28 US$2.400 -4.76% 2,567,637
26-08-27 US$2.520 +3.70% 1,941,408
26-08-26 US$2.430 -3.95% 1,445,009
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.390USD
Average target price
8.917USD
Spread / Average Target
+273.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock